Correcting for targeted and control agent signal differences in paired-agent molecular imaging of cancer cell-surface receptors

Abstract. Paired-agent kinetic modeling protocols provide one means of estimating cancer cell-surface receptors with in vivo molecular imaging. The protocols employ the coadministration of a control imaging agent with one or more targeted imaging agent to account for the nonspecific uptake and retention of the targeted agent. These methods require the targeted and control agent data be converted to equivalent units of concentration, typically requiring specialized equipment and calibration, and/or complex algorithms that raise the barrier to adoption. This work evaluates a kinetic model capable of correcting for targeted and control agent signal differences. This approach was compared with an existing simplified paired-agent model (SPAM), and modified SPAM that accounts for signal differences by early time point normalization of targeted and control signals (SPAMPN). The scaling factor model (SPAMSF) outperformed both SPAM and SPAMPN in terms of accuracy and precision when the scale differences between targeted and imaging agent signals (α) were not equal to 1, and it matched the performance of SPAM for α  =  1. This model could have wide-reaching implications for quantitative cancer receptor imaging using any imaging modalities, or combinations of imaging modalities, capable of concurrent detection of at least two distinct imaging agents (e.g., SPECT, optical, and PET/MR).

[1]  Brian W Pogue,et al.  Development and evaluation of a connective tissue phantom model for subsurface visualization of cancers requiring wide local excision , 2017, Journal of biomedical optics.

[2]  H. Dvorak,et al.  Vascular permeability, vascular hyperpermeability and angiogenesis , 2008, Angiogenesis.

[3]  H. Dvorak,et al.  Why are tumour blood vessels abnormal and why is it important to know? , 2009, British Journal of Cancer.

[4]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Brian W. Pogue,et al.  Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions , 2016, Molecular Imaging and Biology.

[6]  Tayyaba Hasan,et al.  Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas. , 2010, Academic radiology.

[7]  R. Coleman,et al.  Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. , 1984, Anticancer research.

[8]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[9]  Y. Assaraf,et al.  The folate receptor as a rational therapeutic target for personalized cancer treatment. , 2014, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  M F Kijewski,et al.  Absolute activity quantitation in simultaneous 123I/99mTc brain SPECT. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  A. Ullrich,et al.  Kinetics of binding, endocytosis, and recycling of EGF receptor mutants , 1992, The Journal of cell biology.

[12]  Jeih-San Liow,et al.  Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  R. Jain Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[14]  T. Cloughesy,et al.  Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma , 2015, Nature Reviews Cancer.

[15]  T. Hasan,et al.  Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors , 2012, Physics in medicine and biology.

[16]  Vasilis Ntziachristos,et al.  Accuracy of fluorescent tomography in the presence of heterogeneities:study of the normalized born ratio , 2005, IEEE Transactions on Medical Imaging.

[17]  Mamta Khurana,et al.  Quantification of in vivo fluorescence decoupled from the effects of tissue optical properties using fiber-optic spectroscopy measurements. , 2010, Journal of biomedical optics.

[18]  Jason R. Gunn,et al.  In Vivo Quantification of Tumor Receptor Binding Potential with Dual-Reporter Molecular Imaging , 2012, Molecular Imaging and Biology.

[19]  Brian W Pogue,et al.  Microdose fluorescence imaging of ABY-029 on an operating microscope adapted by custom illumination and imaging modules. , 2016, Biomedical optics express.

[20]  Sylvain Gioux,et al.  qF-SSOP: real-time optical property corrected fluorescence imaging. , 2017, Biomedical optics express.

[21]  Adam K Glaser,et al.  Raman-Encoded Molecular Imaging with Topically Applied SERS Nanoparticles for Intraoperative Guidance of Lumpectomy. , 2017, Cancer research.

[22]  Tayyaba Hasan,et al.  Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach. , 2014, Cancer research.

[23]  K. Tichauer,et al.  Generalized paired-agent kinetic model for in vivo quantification of cancer cell-surface receptors under receptor saturation conditions , 2017, Physics in medicine and biology.

[24]  S. Svanberg,et al.  Medical diagnostic system based on simultaneous multispectral fluorescence imaging. , 1994, Applied optics.

[25]  Brian W. Pogue,et al.  High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas , 2011, Molecular Imaging and Biology.

[26]  B. Pogue,et al.  Pixel-based absorption correction for dual-tracer fluorescence imaging of receptor binding potential. , 2014, Biomedical optics express.

[27]  Eben L. Rosenthal,et al.  Beyond the margins: real-time detection of cancer using targeted fluorophores , 2017, Nature Reviews Clinical Oncology.

[28]  Jason S. Lewis,et al.  Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis. , 2017, PET clinics.

[29]  Keith Paulsen,et al.  Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use , 2017, Molecular Imaging and Biology.

[30]  R. Weissleder,et al.  Imaging in the era of molecular oncology , 2008, Nature.

[31]  R. Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Sophie J Deharvengt,et al.  Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo , 2013, Proceedings of the National Academy of Sciences.

[33]  T. Hasan,et al.  Accounting for pharmacokinetic differences in dual-tracer receptor density imaging , 2014, Physics in medicine and biology.

[34]  Walter H Backes,et al.  Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. , 2005, Radiology.

[35]  T. Cloughesy,et al.  Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine , 2017, The Journal of Nuclear Medicine.

[36]  Stephen B. Tuttle,et al.  Magnetic resonance-coupled fluorescence tomography scanner for molecular imaging of tissue. , 2008, The Review of scientific instruments.

[37]  Jonathan T. C. Liu,et al.  Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging , 2015, Physics in medicine and biology.

[38]  Yasuyoshi Watanabe,et al.  [Molecular imaging for drug development]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.

[39]  Tayyaba Hasan,et al.  Comparison of Kinetic Models for Dual-Tracer Receptor Concentration Imaging in Tumors. , 2014, Austin journal of biomedical engineering.

[40]  Michael S Patterson,et al.  Quantification of fluorophore concentration in tissue-simulating media by fluorescence measurements with a single optical fiber. , 2003, Applied optics.

[41]  Linton T. Evans,et al.  Simultaneous In Vivo Fluorescent Markers for Perfusion, Protoporphyrin Metabolism, and EGFR Expression for Optically Guided Identification of Orthotopic Glioma , 2016, Clinical Cancer Research.

[42]  I. Lax,et al.  Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. , 1993, Biochemistry.